2016
DOI: 10.1016/s2213-2600(16)30152-7
|View full text |Cite
|
Sign up to set email alerts
|

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Abstract: SummaryBACKGROUNDTwelve months of oral cyclophosphamide (CYC) has been shown to alter the progression of scleroderma-related interstitial lung disease (SSc-ILD) when compared to placebo. However, toxicity was a concern and without continued treatment the efficacy disappeared by 24 months. We hypothesized that a two-year course of mycophenolate mofetil (MMF) would be safer, better tolerated and produce longer lasting improvements than CYC.METHODSPatients with SSc-ILD meeting defined dyspnea, pulmonary function … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

30
691
3
43

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 877 publications
(767 citation statements)
references
References 29 publications
30
691
3
43
Order By: Relevance
“…The results of the recently published Scleroderma Lung Study-II have confirmed a beneficial outcome of ILD treatment with CYC for 1 year and with MMF for 2 years [30]. On account of better tolerability and lower toxicity of MMF at 3 g/day, MMF is the preferred option for first-line treatment [30]. Indications for introducing oral or intravenous CYC therapy for 6-12 months include ILD cases with severe progressive course, not responding to MMF treatment [30].…”
Section: Interstitial Lung Diseasementioning
confidence: 98%
See 2 more Smart Citations
“…The results of the recently published Scleroderma Lung Study-II have confirmed a beneficial outcome of ILD treatment with CYC for 1 year and with MMF for 2 years [30]. On account of better tolerability and lower toxicity of MMF at 3 g/day, MMF is the preferred option for first-line treatment [30]. Indications for introducing oral or intravenous CYC therapy for 6-12 months include ILD cases with severe progressive course, not responding to MMF treatment [30].…”
Section: Interstitial Lung Diseasementioning
confidence: 98%
“…The results of randomized placebo-controlled clinical trials show that CYC used in the therapy of patients with ILD for several months has enhanced the quality of life of patients, reduced dyspnoea, increased lung function assessed in forced vital capacity and total lung capacity function tests, and improved high-resolution computed tomography changes [27][28][29][30]. The results of the recently published Scleroderma Lung Study-II have confirmed a beneficial outcome of ILD treatment with CYC for 1 year and with MMF for 2 years [30]. On account of better tolerability and lower toxicity of MMF at 3 g/day, MMF is the preferred option for first-line treatment [30].…”
Section: Interstitial Lung Diseasementioning
confidence: 99%
See 1 more Smart Citation
“…Начальная доза МФМ -1000 мг/сут (в два приема), в случае хорошей переносимости ее увеличивают до 2000-3000 мг/сут (в два приема). Недавно закончилось клиническое испытание, в котором сравнивали ЦФ и МФМ [22]. В этом проспективном рандомизированном контролируемом многоцентровом ис-следовании эффективности и переносимости ЦФ (≤2 мг/кг внутрь -1 год и плацебо -1 год) и MФM (≤3 г/сут -2 года) участвовали 142 больных.…”
Section: рис 1 мскт органов грудной клетки больной 61 года выраженunclassified
“…Most importantly, patients with CTD-ILD may benefit from immunosuppressive agents that carry an increased risk of death in patients with IPF. [20][21][22][23] Detailed evaluation for symptoms and signs of underlying CTD should be performed at baseline in all patients with fibrotic ILD, and should be repeated during follow-up since ILD can also develop prior to overt features of CTD. 24 No consensus exists on which autoimmune serology should be routinely performed when screening a broader ILD population for the presence of CTD; however, recent IPF guidelines recommend obtaining a rheumatoid factor (RF), antinuclear antibody (ANA) and anti-cyclic citrullinated peptide (CCP) antibody in patients with suspected IPF.…”
Section: High Resolution Computed Tomographymentioning
confidence: 99%